Anthony Adamis
Director/Board Member bei EYEPOINT PHARMACEUTICALS, INC.
Vermögen: 41 340 $ am 31.03.2024
Profil
Anthony P.
Adamis is the founder of Eyebiotech Ltd.
(founded in 2021) and holds the title of Director.
He is currently working as an Independent Director at EyePoint Pharmaceuticals, Inc., Spiral Therapeutics, Inc., Gyroscope Therapeutics Ltd., Theia Therapeutics, Inc., and Retinal Degeneration Fund.
He is also the Chief Scientific Officer at (OSI).
Eyetech.
Previously, he worked as a Director at Gyroscope Therapeutics Holdings Plc from 2021 to 2022.
He also held the position of Vice President & Global Head-Ophthalmology at Genentech, Inc. and Chief Scientific Officer at Oldtech, Inc. Dr. Adamis completed his undergraduate degree at the University of Illinois and obtained a doctorate from the Pritzker School of Medicine.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 05.01.2024 | 2 000 ( 0,00% ) | 41 340 $ | 31.03.2024 |
Aktive Positionen von Anthony Adamis
| Unternehmen | Position | Beginn |
|---|---|---|
| EYEPOINT PHARMACEUTICALS, INC. | Director/Board Member | 23.06.2022 |
(OSI) Eyetech
 (OSI) Eyetech Medical SpecialtiesHealth Technology OSI Eyetech provides medical services. It is specializee in the development and commercialization of therapeutics to treat diseases of the eye. The company is headquartered in New York City, NY. | Chief Tech/Sci/R&D Officer | - |
| Retinal Degeneration Fund | Director/Board Member | 01.10.2021 |
Gyroscope Therapeutics Ltd.
 Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | Director/Board Member | 01.12.2021 |
Eyebiotech Ltd.
 Eyebiotech Ltd. Pharmaceuticals: MajorHealth Technology Eyebiotech Ltd. develops new generation of therapies for eye diseases. The British company was founded in 2021 by David R. Guyer, Anthony P. Adamis. David R. Guyer has been the CEO since 2021. | Founder | 01.08.2021 |
Spiral Therapeutics, Inc.
 Spiral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Spiral Therapeutics, Inc. manufactures pharmaceutical products. The firm also develops therapies for inner ear disorders. The company was founded by Hugo Peris, Justin S. Hanes and Eugene de Juan in 2016 and is headquartered in San Francisco, CA. | Director/Board Member | 01.10.2021 |
| Theia Therapeutics, Inc. | Director/Board Member | 01.11.2021 |
Ehemalige bekannte Positionen von Anthony Adamis
| Unternehmen | Position | Ende |
|---|---|---|
| GYROSCOPE THERAPEUTICS HOLDINGS PLC | Director/Board Member | 17.02.2022 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | - |
| ░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | - |
Ausbildung von Anthony Adamis
| University of Illinois | Undergraduate Degree |
| Pritzker School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| EYEPOINT PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 9 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Oldtech, Inc.
 Oldtech, Inc. BiotechnologyHealth Technology Oldtech, Inc. was engaged in developing treatments for conditions that affect the back of the eye, including age related macular degeneration (AMD) and diabetic macular edema (DME). The company was headquartered in New York. | Health Technology |
(OSI) Eyetech
(OSI) Eyetech Medical SpecialtiesHealth Technology OSI Eyetech provides medical services. It is specializee in the development and commercialization of therapeutics to treat diseases of the eye. The company is headquartered in New York City, NY. | Health Technology |
Spiral Therapeutics, Inc.
Spiral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Spiral Therapeutics, Inc. manufactures pharmaceutical products. The firm also develops therapies for inner ear disorders. The company was founded by Hugo Peris, Justin S. Hanes and Eugene de Juan in 2016 and is headquartered in San Francisco, CA. | Commercial Services |
Gyroscope Therapeutics Ltd.
Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
| Retinal Degeneration Fund | |
| Theia Therapeutics, Inc. | |
Gyroscope Therapeutics Holdings Plc
 Gyroscope Therapeutics Holdings Plc BiotechnologyHealth Technology Gyroscope Therapeutics Holdings Plc engages in the development of gene therapy beyond rare diseases. It focuses on age-related macular degeneration. The company was founded in 2016 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
Eyebiotech Ltd.
Eyebiotech Ltd. Pharmaceuticals: MajorHealth Technology Eyebiotech Ltd. develops new generation of therapies for eye diseases. The British company was founded in 2021 by David R. Guyer, Anthony P. Adamis. David R. Guyer has been the CEO since 2021. | Health Technology |
